
This study investigated targeting KRAS-mutated metastatic colorectal cancers using combined trametinib and cetuximab. In patient-derived xenograft models, this approach induced stable disease or partial response in 74% compared to 24% with trametinib alone. Prolonged response and low secondary resistance were observed in partial response cases.
Like
Save
Share